UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Breast cancer research : BCR, 2024-03, Vol.26 (1), p.46-46, Article 46

2024

Volltextzugriff (PDF)

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (8), p.3047-3052

2008

Volltextzugriff (PDF)

Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism

Leukemia, 2021-06, Vol.35 (6), p.1621-1630

2021

Volltextzugriff (PDF)

Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy

Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (48), p.17266-17271

2014

Volltextzugriff (PDF)

IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope

PloS one, 2013-06, Vol.8 (6), p.e65203-e65203

2013

Volltextzugriff (PDF)

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

The Journal of clinical investigation, 2016-02, Vol.126 (2), p.585-598

2016

Volltextzugriff (PDF)

B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences - PNAS, 2010-11, Vol.107 (44), p.18956-18960

2010

Volltextzugriff (PDF)

A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer

Breast cancer research : BCR, 2024-02, Vol.26 (1), p.32-32, Article 32

2024

Volltextzugriff (PDF)

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.6991-6991

2022

Volltextzugriff (PDF)

Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma

Electrophoresis, 2014-07, Vol.35 (12-13), p.1828-1836

2014

Volltextzugriff (PDF)

Wnt5a Induces ROR1 to Interact Grb2 to Enhance Ras Activation in Chronic Lymphocytic Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.247-247

2021

Volltextzugriff (PDF)

Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein

Biomedicines, 2024-07, Vol.12 (7), p.1573

2024

Volltextzugriff (PDF)

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Blood, 2019-11, Vol.134 (Supplement_1), p.4274-4274

2019

Volltextzugriff (PDF)

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Blood, 2018-11, Vol.132 (Supplement 1), p.4404-4404

2018

Volltextzugriff (PDF)

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Blood, 2022-11, Vol.140 (Supplement 1), p.3356-3357

2022

Volltextzugriff (PDF)

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Blood, 2019-11, Vol.134 (Supplement_1), p.476-476

2019

Volltextzugriff (PDF)

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Blood, 2020-11, Vol.136 (Supplement 1), p.13-13

2020

Volltextzugriff (PDF)

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1853-1853

2018

Volltextzugriff (PDF)

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Blood, 2018-11, Vol.132 (Supplement 1), p.1862-1862

2018

Volltextzugriff (PDF)

ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice

Proceedings of the National Academy of Sciences - PNAS, 2014-01, Vol.111 (2), p.793-798

2014

Volltextzugriff (PDF)

Normal B Cells Express 51p1-Encoded Ig Heavy Chains That Are Distinct From Those Expressed by Chronic Lymphocytic Leukemia B Cells

The Journal of immunology (1950), 2001-01, Vol.166 (1), p.95-102

2001

Volltextzugriff (PDF)

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

Blood, 2017-12, Vol.130, p.4019-4019

2017

Volltextzugriff (PDF)

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Blood, 2017-12, Vol.130, p.389-389

2017

Volltextzugriff (PDF)

Preclinical evaluation of anti-ROR1 CAR T cells employing a ROR1 binding SCFV derived from the clinical stage mab cirmtuzumab

Journal of clinical oncology, 2020-02, Vol.38 (5_suppl), p.41-41

2020

Volltextzugriff (PDF)

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.2652-2652

2018

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Humans
(12)
Life Sciences & Biomedicine
(9)
Leukemia
(8)
Animals
(6)
Chronic Lymphocytic Leukemia
(6)
Leukemia, Lymphocytic, Chronic, B-Cell - Immunology
(6)
Cancer
(5)
Kinases
(5)
Mice
(5)
Proteins
(5)
B-Lymphocytes - Immunology
(4)
Base Sequence
(4)
Biological Sciences
(4)
Female
(4)
Gene Expression
(4)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(4)
Molecular Sequence Data
(4)
Monoclonal Antibodies
(4)
Multidisciplinary Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(31)
Single Online Journals
(24)
MEDLINE
(12)
Journals@Ovid
(5)
JSTOR
(4)
Nexis Uni
(4)
Wiley Online Library
(2)
Wiley Online Library Full Collection 2018
(2)
Nature Journals
(2)
Springer Nature - Complete Springer Journals
(2)
IngentaConnect Journals
(1)
Ingenta Connect
(1)

7 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism

Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy

IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia

A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma

Wnt5a Induces ROR1 to Interact Grb2 to Enhance Ras Activation in Chronic Lymphocytic Leukemia

Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice

Normal B Cells Express 51p1-Encoded Ig Heavy Chains That Are Distinct From Those Expressed by Chronic Lymphocytic Leukemia B Cells

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Preclinical evaluation of anti-ROR1 CAR T cells employing a ROR1 binding SCFV derived from the clinical stage mab cirmtuzumab

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Suchergebnisse filtern